Key result
nsMRAs improve cardiorenal protection and tolerability in CKD while steroidal MRAs provide cheaper blood pressure lowering.
Why the study?
Classic steroidal MRAs have shown cardiorenal benefits but are constrained by side effects, while newer nonsteroidal MRAs offer improved tolerability and proven outcomes, prompting a need to contrast their respective roles in CKD.
Do nonsteroidal MRAs offer a better balance of efficacy and safety compared to steroidal MRAs in patients with chronic kidney disease?
Do nonsteroidal MRAs offer a better balance of efficacy and safety compared to steroidal MRAs in patients with chronic kidney disease?
Answers are grounded in this paper and cite their sources.
This debate highlights the clinical trade-offs between the novel cardiorenal benefits of nonsteroidal MRAs and the potent antihypertensive efficacy and accessibility of classic steroidal MRAs in managing CKD.
Mineralocorticoid receptor antagonists (MRAs) are a central component of contemporary cardiorenal protection in chronic kidney disease (CKD). Classic steroidal MRAs, spironolactone and eplerenone, have long been used to treat hypertension and heart failure and to reduce albuminuria, but their wider use in CKD has been constrained by hyperkalaemia and endocrine side-effects. Nonsteroidal MRAs (nsMRAs), typified by finerenone, were developed to maintain antiproteinuric and antifibrotic efficacy while improving tissue selectivity, pharmacokinetics, and tolerability. Large outcome trials in type 2 diabetes with albuminuric CKD show that finerenone reduces the risk of kidney failure and major cardiovascular events when added to renin-angiotensin system (RAS) blockade and, more recently, in combination with SGLT2 inhibition. At the same time, the superior blood pressure-lowering capacity, low cost, and global availability of steroidal MRAs remain compelling, particularly in resistant hypertension and resource-constrained settings. This pro/con debate contrasts the case for nsMRAs with that for classic steroidal MRAs and explores how best to deploy each class across heterogeneous CKD populations.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2026) conducted a review in Chronic kidney disease. Nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) vs. Steroidal mineralocorticoid receptor antagonists was evaluated. Nonsteroidal MRAs offer improved tolerability and cardiorenal protection in CKD, while classic steroidal MRAs remain compelling for their blood pressure-lowering capacity and low cost.
Synapse has enriched 10 related papers. Consider them for comparative context: